Submucous uterine fibroid
diseaseOn this page
Also known as submucous leiomyoma of uterus
Summary
Submucous uterine fibroid (MONDO:0001664) is a disease and 2 clinical trials. Top therapeutic interventions include vasopressin and misoprostol acid. A subtype of uterine corpus leiomyoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 2
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | submucous uterine fibroid |
| Mondo ID | MONDO:0001664 |
| DOID | DOID:13222 |
| ICD-10-CM | D25.0 |
| SNOMED CT | 95279007 |
| UMLS | C0153993 |
| MedGen | 509501 |
| GARD | 0022984 |
| Is cancer (heuristic) | no |
Also known as: submucous leiomyoma of uterus
Disease family
This is a subtype of uterine corpus leiomyoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system benign neoplasm › benign muscle neoplasm › benign smooth muscle neoplasm › leiomyoma › uterine corpus leiomyoma › submucous uterine fibroid
Related subtypes (10): subserous uterine fibroid, uterine corpus epithelioid leiomyoma, uterine corpus dissecting leiomyoma, uterus interstitial leiomyoma, uterine corpus myxoid leiomyoma, uterine corpus lipoleiomyoma, uterine corpus bizarre leiomyoma, uterine corpus diffuse leiomyomatosis, uterine corpus apoplectic leiomyoma, uterine corpus cellular leiomyoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 2.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2/PHASE3 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03930069 | PHASE2/PHASE3 | COMPLETED | Vasopressin Injection Versus Misoprostol During Hysteroscopic Myomectomy In Reducing Blood Loss And Operation Time. |
| NCT05898321 | Not specified | UNKNOWN | To Prevent Type I-II Myoma After TCRM Recurrence by Gonadotropin-releasing Hormone (GnRH )Analogues or Mifepristone |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| VASOPRESSIN | 4 | 1 |
| MISOPROSTOL ACID | -1 | 1 |
Related Atlas pages
- Drugs: Vasopressin